12th Oct 2015 09:58
LONDON (Alliance News) - Vernalis PLC said Monday that its partner Tris Pharma Inc has manufactured 3 registration batches of its cough cold product CCP-08, and has begun 12 months of stability testing.
Tris expects to file a new drug application with the stability data with the US Food and Drug Administration in 2016.
Tris Pharma is developing up to six cough cold treatments on behalf of Vernalis.
"We are extremely pleased with the continued progression of CCP-08 and the maturing pipeline with Tris and we look forward to further positive news flow from our cough cold programmes," said Chief Executive Officer Ian Garland in a statement.
Shares in Vernalis were up 3.5% at 75.55 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC